The CLEOPATRA trial demonstrated that the addition of pertuzumab to trastuzumab and docetaxel significantly improves progression-free and OS (56.5 months compared to 40.8 months in the placebo group) in patients with HER2-positive metastatic BC [73]. This evidence concerns the gene ERBB2 and breast cancer.